Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study

Heymer, E.J.; Hawkins, M.M.; Winter, D.L.; Teepen, J.C.; Sunguc, C.; Ronckers, C.M.; Allodji, R.S.; Alessi, D.; Sugden, E.; Belle, F.N.; Bagnasco, F.; Byrne, J.; Bárdi, E.; Garwicz, S.; Grabow, D.; Jankovic, M.; Kaatsch, P.; Kaiser, M.; Michel, G.; Schindera, C.; Haddy, N.; Journy, N.; Česen, Mazić M.; Skinner, R.; Kok, J.L.; Gunnes, M.W.; Wiebe, T.; Sacerdote, C.; Maule, M.M.; Terenziani, M.; Jakab, Z. [Jakab, Zsuzsanna (Gyermekgyógyászat...), szerző] II. Sz. Gyermekgyógyászati Klinika (SE / AOK / K); Winther, J.F.; Lähteenmäki, P.M.; Zadravec, Zaletel L.; Haupt, R.; Kuehni, C.E.; Kremer, L.C.; de, Vathaire F.; Hjorth, L.; Reulen, R.C. ✉

Angol nyelvű Sokszerzős vagy csoportos szerzőségű szakcikk (Folyóiratcikk) Tudományos
Megjelent: BRITISH JOURNAL OF CANCER 0007-0920 1532-1827 130 pp. 976-986 2024
  • SJR Scopus - Oncology: D1
Azonosítók
Background: Childhood cancer survivors are at risk of subsequent gliomas and meningiomas, but the risks beyond age 40 years are uncertain. We quantified these risks in the largest ever cohort. Methods: Using data from 69,460 5-year childhood cancer survivors (diagnosed 1940–2008), across Europe, standardized incidence ratios (SIRs) and cumulative incidence were calculated. Results: In total, 279 glioma and 761 meningioma were identified. CNS tumour (SIR: 16.2, 95% CI: 13.7, 19.2) and leukaemia (SIR: 11.2, 95% CI: 8.8, 14.2) survivors were at greatest risk of glioma. The SIR for CNS tumour survivors was still 4.3-fold after age 50 (95% CI: 1.9, 9.6), and for leukaemia survivors still 10.2-fold after age 40 (95% CI: 4.9, 21.4). Following cranial radiotherapy (CRT), the cumulative incidence of a glioma in CNS tumour survivors was 2.7%, 3.7% and 5.0% by ages 40, 50 and 60, respectively, whilst for leukaemia this was 1.2% and 1.7% by ages 40 and 50. The cumulative incidence of a meningioma after CRT in CNS tumour survivors doubled from 5.9% to 12.5% between ages 40 and 60, and in leukaemia survivors increased from 5.8% to 10.2% between ages 40 and 50. Discussion: Clinicians following up survivors should be aware that the substantial risks of meningioma and glioma following CRT are sustained beyond age 40 and be vigilant for symptoms. © 2024, The Author(s).
Hivatkozás stílusok: IEEEACMAPAChicagoHarvardCSLMásolásNyomtatás
2025-03-30 06:29